Literature DB >> 1570489

Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis.

A Scheja1, A Akesson, K Hørslev-Petersen.   

Abstract

Systemic sclerosis (SSc) is characterized by an excessive accumulation of collagen in skin and internal organs and increased serum concentrations of different connective tissue metabolites have been reported. In this study of 82 patients with SSc, serum concentrations of aminoterminal type III procollagen peptide (PIIINP), smaller PIIINP-related antigens (Fab PIIINP) and hyaluronan (HA) were increased as compared to healthy controls matched for age and sex. Patients with a shorter disease duration (less than 3 years) had higher serum levels of PIIINP and Fab PIIINP than patients with a longer disease duration. The highest serum concentrations of PIIINP and HA were seen in seven patients who died within 2 years.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1570489     DOI: 10.3109/03009749209095054

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  6 in total

1.  The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters.

Authors:  Mette J Nielsen; Anders F Nedergaard; Shu Sun; Sanne S Veidal; Lise Larsen; Qinlong Zheng; Charlotte Suetta; Kim Henriksen; Claus Christiansen; Morten A Karsdal; Diana J Leeming
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

2.  Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma).

Authors:  A Scheja; A Akesson; P Geborek; M Wildt; C B Wollheim; F A Wollheim; U M Vischer
Journal:  Arthritis Res       Date:  2001-02-19

Review 3.  Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment.

Authors:  Alsya J Affandi; Timothy R D J Radstake; Wioleta Marut
Journal:  Semin Immunopathol       Date:  2015-07-14       Impact factor: 9.623

4.  The association of low complement with disease activity in systemic sclerosis: a prospective cohort study.

Authors:  James Esposito; Zoe Brown; Wendy Stevens; Joanne Sahhar; Candice Rabusa; Jane Zochling; Janet Roddy; Jennifer Walker; Susanna M Proudman; Mandana Nikpour
Journal:  Arthritis Res Ther       Date:  2016-10-22       Impact factor: 5.156

5.  Comparison of hyaluronic acid in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus.

Authors:  Bogdan Cylwik; Ewa Gruszewska; Ewa Gindzienska-Sieskiewicz; Otylia Kowal-Bielecka; Lech Chrostek
Journal:  Biochem Med (Zagreb)       Date:  2021-04-15       Impact factor: 2.313

6.  Circulating Collagen Metabolites and the Enhanced Liver Fibrosis (ELF) Score as Fibrosis Markers in Systemic Sclerosis.

Authors:  Chen Chen; Lingbiao Wang; Jinfeng Wu; Meijuan Lu; Sen Yang; Wenjing Ye; Ming Guan; Minrui Liang; Hejian Zou
Journal:  Front Pharmacol       Date:  2022-02-01       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.